The minimum age to start specific immunotherapy with inhalant allergens in children has not been clearly established, and position papers discourage its use in children younger than 5 years.
INTRODUCTION
Concerns over adverse reactions and compliance have led to the development of sublingual-swallow immunotherapy (SLIT) as distinct from, and in addition to, the subcutaneous administration of allergy vaccines. [1] [2] [3] SLIT is gaining clinical acceptance, although no consensus exists regarding its efficacy. 4 SLIT has been proposed as particularly appropriate and safe for children, 5 but few safety data have targeted pediatric populations. 6 -10 Safety is often deduced from studies that include children but do not report their ratio to adult patients. [11] [12] [13] [14] [15] Few studies include children younger than 5 years. 6, 7, 16 The 1993 European Academy of Allergology and Clinical Immunology position paper advises avoidance of immunotherapy for children younger than 5 years. 17 Thus, European health care professionals have been reluctant to prescribe specific immunotherapy in very young children. 18 However, the 1998 World Health Organization position paper merely lists age for initiation of immunotherapy among "research needs" and advises specialist evaluation. 19 The 2001 Allergic Rhinitis and Its Impact on Asthma (ARIA) Workgroup and World Health Organization document states that immunotherapy, including SLIT, should be initiated early in the disease process, but minimum age for onset of treatment is not specified. 20 The 2003 Joint Task Force position paper of the American College of Asthma, Allergy and Immunology and the American Academy of Allergy, Asthma and Immunology mentions age at onset of immunotherapy as a clinical problem of "cooperation." 21 Thus, the position that "there is no absolute cut-off . . . with respect to the youngest age at which allergen immunotherapy should be considered" remains an open-ended research question. 22 In clinical practice, however, prescription of specific immunotherapy is gaining ground in pediatrics. In many regions of Italy, allergy vaccines are supplied free of charge and immunotherapy is administered in hospital for a minimal fee. Thus, the number of young children receiving immunotherapy is increasing in the absence of evidence-based restraints to prescriptions. In this context, we designed a pilot study to evaluate during a 1-year period whether the 5-year cutoff point is relevant in terms of safety for children aged 3 to 7 years already receiving SLIT for asthma and/or rhinoconjunctivitis.
PATIENTS AND METHODS

Design
The study was designed as an observational, multicenter, minimization study of SLIT prescribed for the treatment of rhinoconjunctivitis and/or asthma in children younger than 7 years. Selection criteria balanced a number of diagnostic, clinical, and prognostic factors obtained from a questionnaire. 23, 24 Entry criteria were as follows: age between 36 and 84 months, monosensitization to pollen or mite allergen, intermittent-severe or persistent rhinoconjunctivitis according to ARIA criteria or level I or II allergic asthma according to the Global Initiative for Asthma (GINA) criteria or both rhinoconjunctivitis and asthma, and pharmacologic medication appropriate to each GINA and ARIA staging. Parents were instructed to use the following rescue medications: for rhinitis, nasal fluticasone, 50 g (Flixonase, GlaxoSmithKline, Uxbridge, England) as a nasal spray; for conjunctivitis, levocabastine, 0.5 mg/mL (Livostin, Jansen-Cilag, Birkerød, Denmark) as ocular drops; and for asthma symptoms, salbutamol (Ventolin, GlaxoSmithKline) as metered-dose inhaler. The research question was whether children younger than 5 years have an increase in adverse events with a high dose of SLIT. The primary outcome was the occurrence and the severity of adverse reaction irrespective of triggering dose or phase of treatment (either build-up or maintenance).
Patients
Children were recruited among outpatients who attended the pediatric departments of Milan, Messina, Palermo, Salerno, and Perugia, Italy, between January and December 2002, and observation was continued for at least 1 year until December 2003. Children younger than 84 months at the onset of SLIT were selected according to the minimization criteria listed herein. Diagnosis and staging were performed by a pediatric allergist with the exclusion of relevant nonallergic triggers of rhinitis and asthma. After selection, parents of patients gave written informed consent. The study was approved by the ethical committees of participating centers.
SLIT Schedules
Children were treated with Staloral 300 (Stallergènes, Antony, France). The allergen extract was graded into concentrations of 1, 10, 100, and 300 IR (index of reactivity) per milliliter. The IR is a unit of allergenic activity specific to the Stallergènes laboratory: a 100-IR extract is defined by its capacity to induce a mean wheal diameter of 7 mm in skin prick tests in a panel of 30 patients sensitized to the allergen considered. The build-up phase was performed as suggested by the manufacturer in 11 days with a top dose of 300 IR, and the maintenance phase dose was 300 IR 3 times a week. Drops were deposited under the tongue and held for 1 minute before being swallowed.
Safety
Adverse reactions and changes in treatment schedule were recorded by means of an ad hoc questionnaire. Reaction severity was classified according to a 0-to 5-point scale (Table 1) . 25 For the purpose of analysis, clinicians were allowed to rank the different reaction types as reported in Table 2 . Phase of treatment (build-up or maintenance), dose that elicited the adverse reaction, and the interval between dose and reaction were recorded.
Statistical Analysis
Hypotheses were tested by the Fisher exact test, the null hypothesis being that the median adverse event scores of the children who participated in the intervention would not change because of SLIT before or after 60 months. Data were expressed as nominal categories on a binomial scale, and the distribution of adverse effects by age was analyzed by the binomial test.
RESULTS
Sixty-five children (14 girls and 51 boys; age range, 38 -80 months; mean Ϯ SD age, 60 Ϯ 10 months; median age, 60 months) were observed. They were divided into 2 subgroups: 38 to 60 months (6 girls and 27 boys; mean Ϯ SD age at onset, 52 Ϯ 6.0 months) and 61 to 80 months (8 girls and 24 boys; mean Ϯ SD age at onset, 70 Ϯ 10.6 months). The mean duration of treatment was 246 Ϯ 161 days. The average cumulative dose of SLIT in the study population was 36,900 Ϯ 1,872 IR (36,200 Ϯ 1,227 for the group 5 years or younger and 37,600 Ϯ 2,142 in the older group). Extracts used were house dust mites in 42 patients, grass in 11 patients, olive tree in 5 patients, Parietaria in 4 patients, and cypress pollens in 3 patients.
In the present series, SLIT, administered with a cumulative dose more than 300 times higher than the standard dose recommended with subcutaneous immunotherapy, was tolerated without adverse events in 54 of 65 cases, whereas 11 patients experienced 13 adverse reactions. Table 3 lists reactions according to patient age in the 2 groups: 6 reactions were recorded in 5 patients in the group of patients who started treatment 60 months or younger and 7 reactions were recorded in 6 patients in the group older than 60 months. Six reactions occurred in the build-up phase and 7 in the maintenance phase, all ranging from mild to moderate and not requiring SLIT cessation. Adjustments were necessary in 9 cases with the conventional schedule and in 2 (moderate reaction) with a reduced maintenance dose. Reactions in the maintenance phase occurred 40 to 350 days from onset of SLIT. Dust mite allergen, used in 64.6% of programs, was responsible for 76.9% of adverse reactions. The occurrence of adverse reactions was independent of age ( 2 ϭ 0.0348). The magnitude of adverse effects is illustrated by the joint probability by age of 5 years or younger according to the multiplication rule. Among children 60 months or younger, these probabilities were 0.08 and 0.11 in older children. Analysis of the binomial distribution reveals that the probability of an adverse outcome for a single patient is similar 60 months or younger (0.16; SD, 2.34) and older than 60 months (0.17; SD, 2.20).
DISCUSSION
This is the first study, to our knowledge, to evaluate whether a 5-year age limitation is clinically justified on safety grounds among children receiving SLIT for asthma and allergic rhinitis. In the literature, no absolute prohibition has been linked to a rationale based on a risk increase in patients younger than this age. Caution is recommended in the evaluation of the tradeoffs of immunotherapy for individual patients. However, this 5-year watershed may be a deterrent to the prescription of SLIT at the very age when the allergic march starts and when the early diagnosis of atopy should be made. 26, 27 Furthermore, a preventive effect of specific immunotherapy on the natural history of allergic disease may be lost with later onset of therapy.
28,29
We did not set out to evaluate the safety of SLIT in young children, but evaluated young Italian children who received SLIT as part of the management of their asthma or rhinoconjunctivitis irrespective of the reason why SLIT had been prescribed. This particular formulation has been proven effective in children. 23 Thus, adverse events in response to individual allergens were not evaluated. The main result of this study was that on either side of the 5-year cutoff there was no significant difference in occurrence of adverse reactions. This finding suggests that younger age does not rule out contemplating the prescription of SLIT when clinically indicated. The few adverse reactions that occurred were low in severity. No major clinical differences occurred among these unselected children across the 60-month age limit during a 1-year period of observation. In this series, the unweighted frequency of adverse reactions was 16.9%, which agrees with the findings from selected populations studied under placebo- Abbreviation: SLIT, sublingual-swallow immunotherapy. controlled conditions among whom the rate of adverse reactions to SLIT was 6.25% 13 to 49%.
14 Treatment with SLIT with house dust mites, the build-up phase, and errors in dosage and compliance are among the risk factors for systemic reactions associated with subcutaneous immunotherapy. The waiting period following injection has been set at 30 minutes, because most untoward reactions tend to be immediate. 17, 30 In our series, most adverse effects occurred after SLIT with house dust mites, and 53.8% of reactions occurred during the build-up phase, underscoring the critical clinical point represented by this stage of SLIT. All but 1 reaction occurred within 60 minutes of administration, suggesting another critical clinical phase. All these findings are reminiscent of data from the literature on subcutaneous immunotherapy.
The limits of the present study are those of an observational study of adverse effects, because we could not, by design, evaluate the clinical effects of SLIT in an unselected population of children. Our aim was to examine the situation during a 1-year period in the sociomedical Italian context, where allergy vaccines are more readily available for prescription.
Our data suggest that there is no reason to forbear assessing safety and efficacy of SLIT beyond this pilot study on account of age of 5 years or younger. Because the efficacy of specific immunotherapy is said to be higher among younger children, 18 further well-controlled clinical studies are needed to establish the safety of SLIT among toddlers. These studies should also address the clinical relevance of single allergens as risk factors.
